CAC
RNAM

Cowen and Company’s Avidity Biosciences RNAM Stock Holding History

Cowen and Company’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,129,103
Closed -$210M – 676
2024
Q2 		$210M Sell
5,129,103
-500,000
-9% -$14.3M 5.76% 5
2024
Q1 		$144M Hold
5,629,103
– – 5.56% 3
2023
Q4 		$50.9M Hold
5,629,103
– – 3.34% 4
2023
Q3 		$35.9M Hold
5,629,103
– – 2.51% 6
2023
Q2 		$62.4M Buy
5,629,103
+1,036,137
+23% +$13M 5.17% 3
2023
Q1 		$70.5M Buy
4,592,966
+304,600
+7% +$6.7M 8.28% 2
2022
Q4 		$95.2M Buy
4,288,366
+500,000
+13% +$7.46M 9.95% 2
2022
Q3 		$61.9M Buy
3,788,366
+1,524,216
+67% +$29.2M 5.92% 3
2022
Q2 		$32.9M Buy
+2,264,150
New +$33.7M 3.18% 9

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cowen and Company's RNAM Position: Q3 2024 in Review

Cowen and Company sold out of Avidity Biosciences (RNAM) in Q3 2024, closing a stake of 5,129,103 shares — an estimated $210M sold.

Cowen and Company first reported a position in RNAM in Q2 2022 and held it in 9 quarters. The position peaked at $210M in Q2 2024. 245 funds tracked by Wall St. Rank hold RNAM as of Q3 2024.

  • Cowen and Company reported no remaining Avidity Biosciences position as of Q3 2024 after selling out during the quarter.
  • Cowen and Company sold 5,129,103 Avidity Biosciences shares in Q3 2024, an estimated $210M.
  • Cowen and Company first reported a position in Avidity Biosciences in Q2 2022 and held it in 9 quarters.
  • Cowen and Company's Avidity Biosciences position peaked at $210M in Q2 2024.
  • 245 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2024.

Based on Cowen and Company's 13F filing for Q3 2024, filed 12 Nov 2024.